Lung Function Stable Three Years After Hematopoietic Cell Transplant in Sickle Cell
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell disease (SCD), according to a study published online June 26 in the Annals of the American Thoracic Society.
A. Parker Ruhl, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues examined pulmonary function testing parameters at three years after HCT. Data were obtained for 97 SCD patients who underwent HCT; 55 were available for follow-up at three years.
The researchers found that the median pre-HCT forced expiratory volume in one second (FEV1) was 68.3 and 69.2 percent at baseline and three years post-HCT; diffusing capacity of the lungs for carbon monoxide (DLCO) was 60.5 and 64.6 percent pre-HCT and at three years post-HCT. At three years post-HCT, generalized estimating equations estimated that DLCO percent-predicted increased significantly by 3.7 percent and the six-minute walk distance increased significantly by 25.9 m; relative to pre-HCT, no significant change was seen in percent-predicted FEV1 or forced vital capacity.
"Without the ongoing injury, it's possible that healing of lung tissue might occur, and this finding should help reassure adults living with sickle cell disease who are considering whether to have a low-intensity stem cell transplant procedure that their lung health will not be compromised by the transplant," Ruhl said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Cardiorespiratory Effects of Smoke Fine Particulate Matter From Wildfires Can Persist for Months
THURSDAY, June 5, 2025 -- The cardiorespiratory effects of smoke fine particulate matter (PM2.5), a primary wildfire emission that can spike for months after a wildfire begins...
Multiple Environmental Exposures Jointly Contribute to Asthma Risk
WEDNESDAY, May 28, 2025 -- Air pollution, built environment, and ambient temperature jointly contribute to incident asthma risk, according to a study published online May 15 in...
Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
TUESDAY, May 20, 2025 -- For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.